Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
about
Using electronic health records to predict costs and outcomes in stable coronary artery diseaseCardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.Implications of the PEGASUS-TIMI 54 trial for US clinical practice.Long term health outcomes in patients with a history of myocardial infarction: A population based cohort studyCritical appraisal of ticagrelor in the management of acute coronary syndromeTwelve or 30 months of dual antiplatelet therapy after drug-eluting stentsBenefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction.Novel antiplatelet agents in acute coronary syndrome.Ticagrelor: a review of its use in adults with acute coronary syndromes.The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.Long-term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy.Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].The 10(th) Annual Cardiometabolic Health Congress General Session Highlights.Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.[Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept].Editorial on PEGASUS-TIMI 54.Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
P2860
Q28603610-7BD13CDD-743B-4B20-B37F-C3317D865D79Q30884351-54D00BA8-E08F-4E4A-BF1F-47B31E5648E6Q33589630-231343C8-9127-4D6C-AD39-37424BDC0104Q33801831-B9B30ECC-174A-4283-8AA1-3D041EF7AB28Q33898330-18E9E982-A718-4D19-B97B-0A450962B0D9Q35660767-E7852EC6-4556-4D4E-A70D-3B58DFDC07C6Q35783487-51E58992-F92D-4CE4-8280-DA95FB21C679Q36369122-484D8F8E-5D51-4ADC-8A1C-6451E01B016BQ36706382-525CAFFB-07D7-4D6A-8158-354B5E863117Q38257119-97BDDB23-8F60-4D64-983E-6E4624ABC031Q38352069-8C3065F5-D28F-4BFE-A6CA-8C028C4CAAA0Q38603459-083F375A-875E-492C-A929-330E43DDD1A2Q38675042-3D7C08C8-17B2-4F3B-B433-D40C6977D94DQ38859458-B7951E39-C0C6-449C-929B-33B33BDEF3F3Q38869502-53AD4918-AD40-43FD-A1BC-075686FA8C02Q38950967-554027BD-3CF9-4C85-913B-D7549ED57070Q38974884-337635CB-B401-4209-AFD0-A9A96EE8D523Q40272818-E90669F7-694F-454E-953D-BF6D98C5DEAFQ40470170-BBDF21AE-E99E-41CC-BBCA-FDC54B2D5F00Q41255322-BBFA083F-24F2-42C0-884C-BB1C8EBEB7C5Q43226646-D9B58E8B-30A1-46D6-9A4F-A0DDBAB3940CQ48221932-FD8B5921-B698-4821-8C08-39F687CA9E31Q48761201-9E89BCEB-807B-4110-AB53-14E889DEC0F2Q49908641-57D40D8B-3171-4BCB-ACA9-A7B907B31388Q50625731-86AF9F2E-3AC2-4972-BCA7-9E7BD7BA6A4CQ51306390-C0893271-6976-409A-ABA3-FEE0C368B2F0Q53257151-61BB9413-0DDE-4DC1-ABE3-590C4450EABBQ53418383-D5F081EB-7FE4-4F9B-93D0-1C8137C78CA3Q54375523-E05807D6-EC54-4205-9D29-5527E8F2D5DFQ56384060-C2FCBA41-7A1C-4B19-B1F3-1A39163E0A6F
P2860
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Design and rationale for the P ...... on 54 (PEGASUS-TIMI 54) trial.
@en
type
label
Design and rationale for the P ...... on 54 (PEGASUS-TIMI 54) trial.
@en
prefLabel
Design and rationale for the P ...... on 54 (PEGASUS-TIMI 54) trial.
@en
P2093
P50
P921
P1476
Design and rationale for the P ...... on 54 (PEGASUS-TIMI 54) trial.
@en
P2093
Deepak L Bhatt
Eva C Jensen
Marc Cohen
Marc P Bonaca
Marc S Sabatine
Peter Held
P304
437-444.e5
P356
10.1016/J.AHJ.2013.12.020
P407
P577
2014-01-06T00:00:00Z